Prostate-specific antigen (PSA) is a kind of protein exclusively produced by epithelial prostatic cells and is a significant tumor marker for prostate cancer. Prostate-specific molecule’s elevated presence in blood serum is used to identify prostate cancer among men. Increased levels of PSA are linked with prostatitis, which is an inflammation of the prostate gland, or it is an indication of a benign form of prostatic hyperplasia. The PSA testing, in combination with a digital rectal exam (DRE), is applied to test prostate cancer in asymptomatic men. PSA screening has achieved recognition among clinicians and healthcare providers to identify possible causes of prostate cancer and to identify the root of the problem.
The prostate cancer symptoms may differ from men to men and the PSA level in most healthy men remains below 4 mg/mL, and value above 4mg/mL is a projected value for prostate cancer. Yet, a consensus lacks on the normal PSA levels among clinicians. The ever-increasing accuracy and specificity of diagnostic tools and markers is a key factor encouraging the uptake of the PSA testing.
COVID-19 Impact analysis
The COVID-19 pandemic has interrupted the world and has affected almost every single sector in every corner. Curing patients efficiently over the pandemic crisis has become a substantial challenge for the healthcare industry. Prostate cancer patients are at an escalated risk of COVID-19 infection along with illness and loss of life if infected. Prostate cancer essential services are on hold due to the fluctuating medical and surgical importance. Once precisely organized and to reduce the spread of the virus, prostate cancer patients can adhere to telemedicine, determine lifestyle changes, and maintain social distancing. Prostate cancer patients require to be followed up remotely unless and until the COVID-19 pandemic sets right. Prostate cancer patients have amplified occurrences and mortality from COVID-19 infection due to gender, age, and inclination factors.
Top Impacting Factors
- The PSA blood-based biomarker market is leading due to the growth in prevalence of cancer and satisfactory reimbursement policies.
- The PSA testing market is experiencing growth due to the surge in geriatric population. Furthermore, the increased public awareness about the benefits of prostate cancer screening, technological advancements in testing and treating prostate cancer boost the market growth.
- Yet, the elevated cost of treatment is likely to obstruct the global PSA blood-based biomarker market.
- Furthermore, surge in R&D expenditure in biomarkers is anticipated to drive the growth of the market for PSA blood-based biomarkers.
- Overdiagnosis of clinically irrelevant prostate cancer, coupled with the overstatement of the results, is a major constraint in the adoption of prostate-specific antigen testing. Several reimbursement policies in several developed and developing counties cover annual PSA testing among men with age 50 or above.
- Furthermore, PSA testing is being incorporated as a part of the annual wellness analysis in developed countries such as the U.S. and is expected to generate favourable opportunities for market players.
Market Trends
New Product Launches to Flourish the Market
- A new-found assay named PSA Glycomics Assay reveals numerous glycoforms of PSA in urinary extract, involving sialic acid linkage isomers as well the level of (core-) fucosylation. As per Cure for Cancer Foundation, Astellas Pharma B.V., the European Union, and SCIEX. , using this high-performance PGA, evaluation of PSA glycosylation is achievable for the early finding of prostate cancer.
Surge in Usage of Prostate-specific Antigen (PSA) Blood-based Biomarker Market
Numerous companies are concentrating on organic growth approaches such as product introductions, product approvals, and patenting their products. Inorganic growth plans observed in the market are acquisitions as well as partnerships & collaborations. These endeavors have paved the way for an extension of the business and customer base of market players. The market players are anticipated to have rewarding growth opportunities in the future with the escalating demand for PSA blood-based biomarkers in the global market.
Key Benefits of the Report
- This study presents the analytical depiction of the prostate specific antigen (PSA) blood-based biomarker along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the prostate specific antigen (PSA) blood-based biomarker market share.
- The current market is quantitatively analyzed to highlight thegrowth scenario of the prostate specific antigen (PSA) blood-based biomarker market.
- Porter’s five forces analysis illustrates the potency of buyers and suppliers in the market.
- The report provides a detailed analysis of the prostate specific antigen (PSA) blood-based biomarker market based on competitive intensity and how the competition is expected to take shape in coming years.
Questions Answered in the Prostate Specific Antigen (PSA) Blood-based Biomarker Report
- Which are the leading players active in the prostate specific antigen (PSA) blood-based biomarker market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps?
- What is "prostate specific antigen (PSA) blood-based biomarker "?
- What is "prostate specific antigen (PSA) blood-based biomarker" market prediction in the future?
- Who are the leading global players in the "the prostate specific antigen (PSA) blood-based biomarker" market?
- What are the current trends and predicted trends?
- What are the key benefits of the "the prostate specific antigen (PSA) blood-based biomarker" market report?
Prostate Specific Antigen Report Highlights
| Aspects | Details |
 By Type |
|
 By Application |
|
 By Region |
|
 Key Market Players | OGT (Sysmex Group), F. Hoffmann-La Roche Ltd., Genfit, Randox Laboratories Ltd., Minomic, Cleveland Diagnostics Inc., Nutech cancer biomarkers India pvt. Ltd., Creative Diagnostics, Randox Laboratories Ltd., Decipher Biosciences Inc., Proteomedix |
Loading Table Of Content...
